Ann: Leadership Transition, page-85

EMV could well announce a commercial partner well before the trials are finished.
If trial progress reports are positive which I have no doubt then a big distributor of medical devices such as Stryker, Medtronic, GE, etc would be keen to srtike a deal which could also entail funding.

This is most likely IMO and will drive the share price considerably higher before the first product is sold.

I am also an investor in Curvebeam which is due to IPO in the next couple of months at a $200 mil plus val.
CurveBeam AI is a commercial stage diagnostic company providing specialised first to market imaging equipment with AI driven analysis to target improved clinical assessment for diagnosis, prognosis and management (restoration of function) of musculoskeletal health issues.
Curvebeam just recently struck a distribution deal with Stryker.

It is a mistake to compare EMV with 4DX who has a brilliant product but a very inexperienced MD with whom longer term shareholders have paid for his education imo.